FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238992753> ?p ?o ?g. }

• W4238992753 endingPage "3677" @default.
• W4238992753 startingPage "3668" @default.
• W4238992753 abstract "The influence of interferon- (IFN) pretreatment on the outcome after allogeneic bone marrow transplantation (BMT) in chronic myelogenous leukemia (CML) is controversial. One goal of the German randomized CML Studies I and II, which compare IFN ± chemotherapy versus chemotherapy alone, was the analysis of whether treatment with IFN as compared to chemotherapy had an influence on the outcome after BMT. One hundred ninety-seven (23%) of 856 Ph/bcr-abl–positive CML patients were transplanted. One hundred fifty-two patients transplanted in first chronic phase were analyzed: 86 had received IFN, 46 hydroxyurea, and 20 busulfan. Forty-eight patients (32%) had received transplants from unrelated donors. Median observation time after BMT was 4.7 (0.7 to 13.5) years. IFN and chemotherapy cohorts were compared with regard to transplantation risks, duration of treatments, interval from discontinuation of pretransplant treatment to BMT, conditioning therapy, graft-versus-host disease prophylaxis and risk profiles at diagnosis and transplantation, and IFN cohorts also with regard to performance and resistance to IFN. Outcome of patients receiving related or unrelated transplants pretreated with IFN, hydroxyurea, or busulfan was not significantly different. Five-year survival after transplantation was 58% for all patients (57% for IFN, 60% for hydroxyurea and busulfan patients). The outcome within the IFN group was not different by duration of prior IFN therapy more or less than 5 months, 1 year, or 2 years. In contrast, a different impact was observed in IFN-pretreated patients depending on the time of discontinuation of IFN before transplantation. Five-year survival was 46% for the 50 patients who received IFN within the last 90 days before BMT and 71% for the 36 patients who did not (P = .0057). Total IFN dosage had no impact on survival after BMT. We conclude that outcome after BMT is not compromised by pretreatment with IFN if it is discontinued at least 3 months before transplantation. Clear candidates for early transplantation should not be pretreated with IFN." @default.
• W4238992753 created "2022-05-12" @default.
• W4238992753 creator A5004265161 @default.
• W4238992753 creator A5004517634 @default.
• W4238992753 creator A5016147985 @default.
• W4238992753 creator A5017002895 @default.
• W4238992753 creator A5034673327 @default.
• W4238992753 creator A5035666187 @default.
• W4238992753 creator A5035964802 @default.
• W4238992753 creator A5051755490 @default.
• W4238992753 creator A5052479430 @default.
• W4238992753 creator A5060138510 @default.
• W4238992753 creator A5063350015 @default.
• W4238992753 creator A5063548222 @default.
• W4238992753 creator A5066314590 @default.
• W4238992753 creator A5066994665 @default.
• W4238992753 creator A5067841095 @default.
• W4238992753 creator A5071724466 @default.
• W4238992753 creator A5072582820 @default.
• W4238992753 creator A5084862920 @default.
• W4238992753 creator A5091014964 @default.
• W4238992753 creator A5091397639 @default.
• W4238992753 creator A5091537377 @default.
• W4238992753 date "1999-12-01" @default.
• W4238992753 modified "2023-09-26" @default.
• W4238992753 title "Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure" @default.
• W4238992753 cites W1642082766 @default.
• W4238992753 cites W188630774 @default.
• W4238992753 cites W1893871329 @default.
• W4238992753 cites W1928548710 @default.
• W4238992753 cites W2025383600 @default.
• W4238992753 cites W2028896946 @default.
• W4238992753 cites W2038048752 @default.
• W4238992753 cites W2038750132 @default.
• W4238992753 cites W2066068945 @default.
• W4238992753 cites W2071891730 @default.
• W4238992753 cites W2117806883 @default.
• W4238992753 cites W2120756704 @default.
• W4238992753 cites W2292226371 @default.
• W4238992753 cites W2293615862 @default.
• W4238992753 cites W2403285790 @default.
• W4238992753 cites W2587781815 @default.
• W4238992753 cites W60081501 @default.
• W4238992753 doi "https://doi.org/10.1182/blood.v94.11.3668.423a31_3668_3677" @default.
• W4238992753 hasPublicationYear "1999" @default.
• W4238992753 type Work @default.
• W4238992753 citedByCount "0" @default.
• W4238992753 crossrefType "journal-article" @default.
• W4238992753 hasAuthorship W4238992753A5004265161 @default.
• W4238992753 hasAuthorship W4238992753A5004517634 @default.
• W4238992753 hasAuthorship W4238992753A5016147985 @default.
• W4238992753 hasAuthorship W4238992753A5017002895 @default.
• W4238992753 hasAuthorship W4238992753A5034673327 @default.
• W4238992753 hasAuthorship W4238992753A5035666187 @default.
• W4238992753 hasAuthorship W4238992753A5035964802 @default.
• W4238992753 hasAuthorship W4238992753A5051755490 @default.
• W4238992753 hasAuthorship W4238992753A5052479430 @default.
• W4238992753 hasAuthorship W4238992753A5060138510 @default.
• W4238992753 hasAuthorship W4238992753A5063350015 @default.
• W4238992753 hasAuthorship W4238992753A5063548222 @default.
• W4238992753 hasAuthorship W4238992753A5066314590 @default.
• W4238992753 hasAuthorship W4238992753A5066994665 @default.
• W4238992753 hasAuthorship W4238992753A5067841095 @default.
• W4238992753 hasAuthorship W4238992753A5071724466 @default.
• W4238992753 hasAuthorship W4238992753A5072582820 @default.
• W4238992753 hasAuthorship W4238992753A5084862920 @default.
• W4238992753 hasAuthorship W4238992753A5091014964 @default.
• W4238992753 hasAuthorship W4238992753A5091397639 @default.
• W4238992753 hasAuthorship W4238992753A5091537377 @default.
• W4238992753 hasConcept C126322002 @default.
• W4238992753 hasConcept C141071460 @default.
• W4238992753 hasConcept C203014093 @default.
• W4238992753 hasConcept C2776694085 @default.
• W4238992753 hasConcept C2776960273 @default.
• W4238992753 hasConcept C2777408962 @default.
• W4238992753 hasConcept C2778461978 @default.
• W4238992753 hasConcept C2778715236 @default.
• W4238992753 hasConcept C2779316324 @default.
• W4238992753 hasConcept C2780007613 @default.
• W4238992753 hasConcept C2780611847 @default.
• W4238992753 hasConcept C2911091166 @default.
• W4238992753 hasConcept C71924100 @default.
• W4238992753 hasConcept C90924648 @default.
• W4238992753 hasConceptScore W4238992753C126322002 @default.
• W4238992753 hasConceptScore W4238992753C141071460 @default.
• W4238992753 hasConceptScore W4238992753C203014093 @default.
• W4238992753 hasConceptScore W4238992753C2776694085 @default.
• W4238992753 hasConceptScore W4238992753C2776960273 @default.
• W4238992753 hasConceptScore W4238992753C2777408962 @default.
• W4238992753 hasConceptScore W4238992753C2778461978 @default.
• W4238992753 hasConceptScore W4238992753C2778715236 @default.
• W4238992753 hasConceptScore W4238992753C2779316324 @default.
• W4238992753 hasConceptScore W4238992753C2780007613 @default.
• W4238992753 hasConceptScore W4238992753C2780611847 @default.
• W4238992753 hasConceptScore W4238992753C2911091166 @default.
• W4238992753 hasConceptScore W4238992753C71924100 @default.
• W4238992753 hasConceptScore W4238992753C90924648 @default.
• W4238992753 hasIssue "11" @default.

• next